Gilead Sciences (XTER:GIS) Scaled Net Operating Assets : 0.66 (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Gilead Sciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gilead Sciences's operating assets for the quarter that ended in Sep. 2024 was €44,589 Mil. Gilead Sciences's operating liabilities for the quarter that ended in Sep. 2024 was €11,610 Mil. Gilead Sciences's Total Assets for the quarter that ended in Jun. 2024 was €49,775 Mil. Therefore, Gilead Sciences's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.66.

Gilead Sciences Scaled Net Operating Assets Historical Data

The historical data trend for Gilead Sciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Scaled Net Operating Assets Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.37

0.63

0.65

0.63

0.62

Gilead Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.66	0.64	0.61	0.70	0.66

Competitive Comparison of Gilead Sciences's Scaled Net Operating Assets

For the Drug Manufacturers - General subindustry, Gilead Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Scaled Net Operating Assets falls into.

Gilead Sciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gilead Sciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(50307.537	-	13194.713)	/	59633.424
=	0.62

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	56968.625	-	6661.088
=	50307.537

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	36107.792	-	21264.313	-	1648.766
=	13194.713

Gilead Sciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(44588.688	-	11610.286)	/	49774.891
=	0.66

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	49127.025	-	4538.337
=	44588.688

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	32557.635	-	19314.737	-	1632.612
=	11610.286

Gilead Sciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XTER:GIS) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).